

Emergent BioSolutions Inc.  
Form 4  
May 26, 2016

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Harsanyi Zsolt

(Last) (First) (Middle)

400 PROFESSIONAL DR, SUITE 400

(Street)

GAITHERSBURG, MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Emergent BioSolutions Inc. [EBS]

3. Date of Earliest Transaction  
(Month/Day/Year)  
05/24/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount (A) or Price (D)		
Common Stock <sup>(1)</sup>	05/24/2016		M		7,200 A \$ 16.13	41,685	D
Common Stock <sup>(1)</sup>	05/24/2016		S		7,200 D \$ 42.26 <sup>(2)</sup>	34,485	D
Common Stock <sup>(3)</sup>	05/24/2016		M		7,200 A \$ 22.02	41,685	D
Common Stock <sup>(3)</sup>	05/24/2016		S		7,200 D \$ 42.26 <sup>(4)</sup>	34,485	D
	05/24/2016		M		2,400 A	36,885	D

Edgar Filing: Emergent BioSolutions Inc. - Form 4

Common Stock <u>(5)</u>					\$				14.66
Common Stock <u>(5)</u>	05/24/2016	S	2,400	D	\$	42.34	34,485	D	<u>(6)</u>
Common Stock <u>(7)</u>	05/25/2016	M	4,800	A	\$	14.25	39,285	D	
Common Stock <u>(7)</u>	05/25/2016	S	4,800	D	\$	42.41	34,485	D	<u>(8)</u>
Common Stock <u>(9)</u>	05/25/2016	M	6,267	A	\$	20.44	40,752	D	
Common Stock <u>(9)</u>	05/25/2016	S	6,267	D	\$	42.41	34,485	D	<u>(10)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 16.13	05/24/2016		M	7,200	05/20/2013 <sup>(11)</sup>	05/20/2020	Common Stock	7,200
Stock Option	\$ 22.02	05/24/2016		M	7,200	05/19/2014 <sup>(11)</sup>	05/19/2022	Common Stock	7,200
Stock Option	\$ 14.66	05/24/2016		M	2,400	05/17/2015 <sup>(11)</sup>	05/17/2019	Common Stock	2,400
Stock Option	\$ 14.25	05/25/2016		M	4,800	05/23/2016 <sup>(11)</sup>	05/22/2021	Common Stock	2,400

Stock Option (Common Stock)	\$ 20.44	05/25/2016	M	6,267	05/22/2016 <sup>(11)</sup>	05/22/2022	Common Stock	6,267
--------------------------------------	----------	------------	---	-------	----------------------------	------------	-----------------	-------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Harsanyi Zsolt 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879			X	

## Signatures

/s/ Eric Burt,  
attorney-in-fact

05/26/2016

\_\_Signature of Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Consists of an option granted under the company's stock incentive plan on May 20, 2010.
  - (2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.10 to \$42.37, inclusive.
  - (3) Consists of an option granted under the company's stock incentive plan on May 19, 2011.
  - (4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.06 to \$42.37, inclusive.
  - (5) Consists of an option granted under the company's stock incentive plan on May 17, 2012.
  - (6) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.25 to \$42.38, inclusive.
  - (7) Consists of an option granted under the company's stock incentive plan on May 23, 2013.
  - (8) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.17 to \$42.53, inclusive.
  - (9) Consists of an option granted under the company's stock incentive plan on May 22, 2014.
  - (10) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.12 to \$42.52, inclusive.
  - (11) All options vested in three equal installments on the anniversary date of the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.